"UPMC Susquehanna is a hospital located in Williamsport, Pa. Visit our website to learn more about the conditions we treat and the services we offer. Schedule your appointment today. UPMC is committed to protecting our communities from the spread of COVID-19. We continue to require people who come to any UPMC facility to wear a facemask that covers their nose and mouth and to practice other preventative efforts like social distancing, even if fully vaccinated."

During the past decade, UPMC Susquehanna conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 36 clinical trials were completed, i.e. on average, 70.6% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 32 clinical trials were completed. i.e. 213.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UPMC Susquehanna" #1 sponsor was "National Cancer Institute (NCI)" with 39 trials, followed by "SWOG Cancer Research Network" with 18 trials sponsored, "Alliance for Clinical Trials in Oncology" with 8 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 5 trials sponsored and "NRG Oncology" with 5 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UPMC Susquehanna" #1 collaborator was "National Cancer Institute (NCI)" with 33 trials as a collaborator, "NRG Oncology" with 6 trials as a collaborator, "Canadian Cancer Trials Group" with 4 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator and "NCIC Clinical Trials Group" with 3 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "UPMC Susquehanna" are "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Invasive Breast Carcinoma" (6 trials), "HER2/Neu Negative" (5 trials) and "Recurrent Breast Carcinoma" (5 trials). Many other conditions were trialed in "UPMC Susquehanna" in a lesser frequency.

Most popular intervention types in "UPMC Susquehanna" are "Drug" (59 trials), "Other" (59 trials), "Biological" (33 trials), "Procedure" (13 trials) and "Radiation" (5 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (38 trials), "Quality-of-Life Assessment" (27 trials), "Questionnaire Administration" (12 trials), "Docetaxel" (10 trials) and "Placebo Administration" (10 trials). Other intervention names were less common.

The vast majority of trials in "UPMC Susquehanna" are 61 trials for "All" genders, 10 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "UPMC Susquehanna". undefined are not yet recruiting, 14 are recruiting, 46 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in UPMC Susquehanna, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in UPMC Susquehanna, 0 "Phase 1" clinical trials were conducted, 30 "Phase 2" clinical trials and 48 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".